Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2699876
Reference Type
Journal Article
Title
Interaction of nanoparticles with immunocompetent cells: nanosafety considerations
Author(s)
Boraschi, D; Costantino, L; Italiani, P
Year
2012
Is Peer Reviewed?
1
Journal
Nanomedicine
ISSN:
1743-5889
EISSN:
1748-6963
Volume
7
Issue
1
Page Numbers
121-131
PMID
22191781
DOI
10.2217/NNM.11.169
Web of Science Id
WOS:000300212600021
Abstract
Intentional delivery of high doses of nanoparticle-based drugs or diagnostic/imaging systems sets a new scenario in safety evaluation, compared with the environmentally borne unintentional exposure to engineered nanoparticles. Intravenously administered nanomedicines immediately interact with blood components such as serum proteins, changing their own characteristics and consequently the features of their interaction with cells and tissues. Of major importance is the interaction of nanomedicines with the immune system, which is essential in the recognition and elimination of foreign dangerous agents. Nanomedicines need to avoid immune recognition in order to reach their therapeutic target and display their effect, should not trigger defensive mechanisms that can damage the body tissues (e.g., complement activation or inflammation) and should not interfere with immunocompetent cells in order to avoid promoting immune-related diseases. This review will briefly cover these issues, and propose some knowledge-based approaches for future 'safe-by-design' nanomedicines.
Keywords
immune response; immunosafety; inflammation; nanomedicines; targeted delivery
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity